Loading quotes...

Forecast

The analysts' average price target is €43.86 (+139.02%). The median is €37.72 (+105.56%).

Buy	9
Hold	0
Sell	0

News Go to news feed

Takeover speculation lifts GH Research stock sharply in premarket

GH Research shares rose 16.4% premarket to $31.34 after reports that Eli Lilly is in advanced takeover talks with AtaiBeckley, sparking speculation of further M&A activity in the psychedelics sector. An RBC analyst viewed GH Research as the main beneficiary of the news and reiterated expectations of targeted interest from large pharma firms in the pipeline, fueling institutional buying. Recent positive signals from the FDA and a government regulation to accelerate the development of psychedelic therapies also provided support. » More on de.investing.com
GH Research PLC announces at-the-market stock offering of up to US$200 million

GH Research PLC has entered into an agreement with Stifel for an at-the-market offering pursuant to which the company may sell common shares from time to time with an aggregate value of up to US$200 million. The sales will be made pursuant to Rule 415(a)(4) of the Securities Act and are covered by a previously filed registration statement on Form F-3. A prospectus supplement and related documents have been filed with the SEC and are available as exhibits to Form 6-K. » More on de.investing.com
GH Research calls annual general meeting for June 25 in Dublin

GH Research has informed its shareholders of an annual general meeting to be held on June 25, 2026 at 13:30 Irish time at Joshua Dawson House in Dublin. The company is making the agenda, proxy materials and voting cards available for registered shareholders and brokers. At the same time, the directors’ report and the 2025 financial statements prepared under Irish law have been published; the information is provided based on a recent SEC filing. » More on de.investing.com

Financials

In the last quarter, GH RESEARCH PLC had revenue of €0 and net profit of -€13.27M

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-13.27M	68.39%
EBITDA	-13.19M	68.97%

Fundamentals

Metric	Value
Market capitalization	€1.23B
Number of shares	68.64M
52-week high/low	€28.24 - €10.81
Dividends	No
Beta	1.33
P/E ratio	-19.99
PEG ratio	0.70
P/B ratio	3.70
P/S ratio	0.00

Company profile

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.